Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

Along with first-line PDL1-positive NSCLC, Libtayo is also used to treat two forms of skin cancer – cutaneous squamous cell carcinoma and basal cell carcinoma. Merck claims adjuvant win in ...

A single-center study suggests the surgery is safe and effective even when tumors are large or located in high-risk areas.

More than one-quarter of blood or marrow transplant survivors developed cutaneous malignant neoplasms, according to study results.Researchers identified several risk factors, including older age, ...

Race, age, and sex were predictors of survival in patients with SCC of the upper esophagus, highlighting the need to address disparities in esophageal SCC management.

National Cancer Institute, Bethesda, Maryland, USA Background: Oesophageal squamous cell carcinoma (OSCC) has a very poor prognosis, which is largely due to late diagnosis. Successful early detection ...

AC will not go away on its own. While it may not look like much in its very early stages, it is serious and requires diagnosis and treatment because it can progress to squamous cell carcinoma. If you ...